Quarterly ResultAug 5, 2026, 05:14 PM
Cytek Q2 Net Loss Widens to $12.16M; Revenue Up 5.6% to $48.14M
AI Summary
Cytek Biosciences reported a widened net loss of $12.16 million for the second quarter of 2026, compared to a net loss of $5.58 million in the prior year. Total revenue increased by 5.6% to $48.14 million. For the first six months of 2026, the company's net loss reached $31.02 million, up from $16.99 million in the same period last year, while total revenue grew to $92.28 million. The company also recognized a $1.6 million impairment loss on a non-marketable equity investment during the quarter.
Key Highlights
- Q2 2026 net loss widened to $(12.16) million from $(5.58) million YoY.
- Q2 2026 total revenue increased 5.6% to $48.14 million.
- H1 2026 net loss widened to $(31.02) million from $(16.99) million YoY.
- H1 2026 total revenue increased to $92.28 million.
- Cash and cash equivalents decreased to $73.85 million as of June 30, 2026.
- Net cash used in operating activities was $(1.37) million for H1 2026.
- Recognized a $1.6 million impairment loss on a non-marketable equity investment in Q2 2026.
- Total stockholders' equity decreased to $321.95 million from $341.74 million.
Price Impact
More from CTKB